Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

Background: To date, coronavirus disease 2019 (COVID-19) becomes increasingly fierce
due to the emergence of variants. Rapid herd immunity through vaccination is needed to …

Background Despite high vaccine coverage and effectiveness, the incidence of symptomatic
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA
BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was …

The development of effective vaccines to combat infectious diseases is a complex multi-year
and multi-stakeholder process. To accelerate the development of vaccines for coronavirus …

Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Early responses to vaccination are important for shaping both humoral and cellular
protective immunity. Dissecting innate vaccine signatures may predict immunogenicity to …

Background Although the BNT162b2 COVID-19 vaccine is known to induce IgG neutralizing
antibodies in serum protecting against COVID-19, it has not been studied in detail whether it …

Importance With the evidence of waning immunity of the mRNA vaccine BNT162b2 (Pfizer-
BioNTech), a nationwide third-dose (booster) vaccination campaign was initiated in Israel …